The results revealed that all three anti-VEGF drugs exhibited several similar AEs, including endophthalmitis, retinal vein occlusion, retinal artery occlusion, glaucoma, dry eye syndrome, and additional AEs not mentioned in the drug’s prescribing information. This evidence concerns the gene VEGFA and endophthalmitis.